Summary of Corning Jereh Conference Call Company Overview - **Company**: Corning Jereh - **Key Products**: KN026, GSK003, KN035, GSKN016, GSKN027, GSKN0,333, and others - **Industry**: Oncology, specifically focusing on Antibody-Drug Conjugates (ADCs) Core Insights and Arguments - **KN026 Approval and Market Potential**: Expected approval in July 2026 for second-line and above HER2-positive gastric cancer, with peak sales anticipated to exceed 3 billion RMB [2][3] - **GSK003 Development**: A HER2 bispecific ADC using glycosylation site-specific conjugation technology, showing better efficacy and safety than existing single-target ADCs like TDM1. Expected to report second-line HER2-positive breast cancer data in 2026, with peak sales projected over 2.5 billion RMB [2][3] - **Technological Platforms**: Corning Jereh has two key platforms: glycosylation site-specific conjugation, which is more efficient than Synaffix, and a subcutaneous administration platform that enhances patient compliance [6][8] - **ADC Market Growth**: The ADC market has seen rapid growth, with over 10 billion USD in business development transactions globally last year, and total sales exceeding 12 billion USD, a 36% year-on-year increase [7][8] Clinical Data and Efficacy - **KN026 Clinical Performance**: In trials for HER2-positive gastric cancer, KN026 demonstrated mPFS and MOS superior to existing therapies, with an HR value below 0.3, indicating a significant reduction in disease progression and mortality risk [10][11] - **GSK003 in Ovarian Cancer**: Showed high ORR in platinum-resistant ovarian cancer, with low adverse reaction rates, indicating its potential as a significant treatment option [12] - **GSKN016 Development**: A dual-target ADC that is currently in the pipeline, expected to show promising safety and efficacy data in upcoming trials [15] Financial Outlook and Investment Recommendations - **Revenue Projections**: KN026's domestic sales peak is expected to exceed 3 billion RMB, while GSK003 is projected to reach 2.6 billion RMB. The company achieved profitability in 2024, primarily due to licensing fees from GSKN003 and sales of KN035 [6][19] - **Investment Rating**: The target price is set at 14.3 HKD, with a buy rating reflecting a 27% upside potential from the current closing price [19] Additional Noteworthy Points - **Pipeline Innovations**: The company is developing several innovative dual antibodies and combination formulations, which are at various clinical stages and may capture significant market share [8][9] - **Regulatory Milestones**: Key regulatory events are anticipated in 2026, including the approval of KN026 and GSK003, which could significantly enhance market potential [9][16] - **Emerging Products**: Other products like GSKN0,333 and GSKN027 are also in development, focusing on enhancing treatment efficacy and patient compliance [14][18]